Microinflammation in hemodialysis is related to a preactivated subset of monocytes.
Increased percentage of monocytes with low CD14 expression and that co-express CD16 (CD14+/CD16+) have been reported in hemodialysis (HD) patients. We sought to determine whether CD14+/CD16+ monocytes in HD therapy are sensibilized cells to a proinflammatory activity. Cells from 32 HD patients, and from 9 Systemic Lupus Erythematosus (SLE), 9 individuals with human immunodeficiency virus (HIV)-1- and 15 healthy controls were studied. Cells were analyzed by means of flow cytometry for CD14/CD16 expression and immune function (cytokine, chemokines, and sialoadhesin expression), and phagocytosis. Increased percentage of CD14+/CD16+ monocytes was observed in HD patients. Compared with CD14++ monocytes, the CD14+/CD16+ monocytes exhibited increased expression of proinflammatory cytokines and markers of differentiated cells. In addition, these monocytes showed an increased phagocytic activity. Similarly, CD14+/CD16+ monocytes from SLE and HIV patients showed increased inflammatory activity as compared with CD14++ cells. These results support that CD14+/CD16+ monocytes from HD patients evidence characteristics of primed prestimulated proinflammatory cells, similar to data observed in SLE and HIV.
Ramirez
Rafael
R
Unidad de Investigación, Servicio de Nefrología, Hospital Universitario Reina Sofía, Córdoba, Spain. manuelr.ramirez.sspa@juntadeadalucia.es
Carracedo
Julia
J
Berdud
Isabel
I
Carretero
Diana
D
Merino
Ana
A
Rodríguez
Mariano
M
Tetta
Ciro
C
Martín-Malo
Alejandro
A
Aljama
Pedro
P
D000328:Adult; D016022:Case-Control Studies; D005434:Flow Cytometry; D015658:HIV Infections / Q000276:immunology; D006801:Humans; D016130:Immunophenotyping; D007249:Inflammation / Q000209:etiology*; D018950:Lipopolysaccharide Receptors / Q000032:analysis; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology*; D010587:Phagocytosis; D017452:Receptors, IgG / Q000032:analysis; D006435:Renal Dialysis / Q000009:adverse effects*
D018950:Lipopolysaccharide Receptors; D017452:Receptors, IgG